FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $89,000 | -10.1% | 3,975 | 0.0% | 0.01% | -75.0% |
| Q2 2022 | $99,000 | -35.7% | 3,975 | 0.0% | 0.02% | -17.2% |
| Q1 2022 | $154,000 | -33.9% | 3,975 | 0.0% | 0.03% | -27.5% |
| Q4 2021 | $233,000 | -7.2% | 3,975 | -6.0% | 0.04% | -11.1% |
| Q3 2021 | $251,000 | -31.6% | 4,230 | 0.0% | 0.04% | -22.4% |
| Q2 2021 | $367,000 | +5.2% | 4,230 | 0.0% | 0.06% | -3.3% |
| Q1 2021 | $349,000 | -9.4% | 4,230 | 0.0% | 0.06% | -9.1% |
| Q4 2020 | $385,000 | +127.8% | 4,230 | 0.0% | 0.07% | +106.2% |
| Q3 2020 | $169,000 | +76.0% | 4,230 | +51.4% | 0.03% | +88.2% |
| Q2 2020 | $96,000 | – | 2,794 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |